Research & Education
CURE Expert Connections
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Despite Prevalence, Pain Management May Be Undermanaged in Patients with MPNs
More than 40 percent of patients with a myeloproliferative neoplasm reported that they were unsatisfied with their current pain management strategy.
Study Investigates Quality of Life in Patients With MPNs
In the MEASURE trial, researchers examined the affect symptom burden associated with myeloproliferative neoplasms has on patients’ lives.
Scott Hamilton: When Fear Flips
For this episode of the CURE Talks Cancer podcast, we spoke with Scott Hamilton, an Olympic gold medalist, cancer survivor and founder of the Scott Hamilton CARES Foundation
CURE Honors Nine Who Help People with Rare Blood Cancers
Beth Fand Incollingo
At the MPN Heroes Event, Olympic skater Scott Hamilton discusses importance of advocacy and research.
Expert Talks Side Effects of PV Treatment
Srdan Verstovsek, M.D., Ph.D.
While Jakafi has been providing promising outcomes so far, there are still some side effects that patients and providers should look out for.
Smoking May Increase Risk for Developing Myeloproliferative Neoplasms
Kristie L. Kahl
A Danish study demonstrated smokers were 2.5 times more likely to develop a myeloproliferative neoplasm compared with their non-smoking counterparts.
Polycythemia Vera Treatments Underused Despite Recommendation
Two treatments that may help patients with a potentially deadly blood cancer live longer and prevent the incidence of thrombosis (blood clots) are being underused.
Encouraging Preliminary Results in Myelofibrosis Trial Lead to Enhancements in Phase 2
After seeing encouraging phase 1 results, the phase 2 portion of a clinical trial currently evaluating the efficacy of the BET inhibitor CPI-0610 in patients with myelofibrosis has been enhanced and expanded.
Treating Polycythemia Vera That Doesn't Respond to Hydroxyurea
For many patients with polycythemia vera, hydroxyurea is a beneficial first-line treatment. But that’s not the case for everyone. One expert discusses which drugs should be used next.
Understanding Mutations May Predict Outcomes in Myeloproliferative Neoplasms
Understanding the type of MPN can affect how care is carried out and how well it may work.
Not a member?
Sign up now!
Continue without login
OPTIONAL INFORMATION: The following information helps us tailor CURE to fit your needs
Please type below what best describes your interests and click on the selection(s):
I am a:
Please list other: